Peter J. Farago, MD. Dr. Farago, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.
The period immediately following release from incarceration is associated with an elevated risk of overdose among those with opioid use disorder. In this randomized trial, researchers were able to show that long-acting injectable buprenorphine (Sublocade) is a feasible and effective treatment for this high-risk population.